First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC).
ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced RCC: 3-Year Follow-up from the Phase 3 CheckMate 9ER Trial urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to sunitinib, regardless of IMDC risk scoreThese three-year data – with a median follow-up of 44 months – from CheckMate -9ER r.
BMS and Exelixis report three-year results for combination treatment in kidney cancer pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.